KR930702029A - Homozygous Immunoglobulins - Google Patents
Homozygous ImmunoglobulinsInfo
- Publication number
- KR930702029A KR930702029A KR1019930700605A KR930700605A KR930702029A KR 930702029 A KR930702029 A KR 930702029A KR 1019930700605 A KR1019930700605 A KR 1019930700605A KR 930700605 A KR930700605 A KR 930700605A KR 930702029 A KR930702029 A KR 930702029A
- Authority
- KR
- South Korea
- Prior art keywords
- antibody
- pharmaceutical composition
- homozygous
- antigen
- monoclonal antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
항원에 대한 높은 결합 활성을 갖는 동종접합된 항체는 치료 활성을 증가시키고, 제약 및 진단 조성물에 이용된다. 동일한 항원 결정 인자에 결합하는 IgG군 단일 클론 항체로부터 통상적으로 제조된 동종접합체는 합성 가교에 의해 공유적으로 결합된다. 동종접합체는 선택된 항원에 대해 4가, 6가 이상의 IgG 유사분자를 제공하기 위하여 2개 이상의 면역 글로불린 단량체로 이루어진다.Homoconjugated antibodies with high binding activity to the antigen increase the therapeutic activity and are used in pharmaceutical and diagnostic compositions. Homozygotes commonly prepared from IgG group monoclonal antibodies that bind to the same antigenic determinants are covalently linked by synthetic crosslinking. Homozygotes consist of two or more immunoglobulin monomers to provide tetravalent, hexavalent or higher IgG analog molecules for the selected antigen.
동종접합체는 태반을 통과할 수 있다. 또한 이러한 동종접합체를 사용하는 치료방법이 제공된다.Homozygotes can cross the placenta. Also provided are methods of treatment using such homozygotes.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.
제1도는 x축은 체류시간이고 y축은 A280인, IgG동종접합 혼합물의 FPLC프로필의 크로마토그램을 나타내고, A,B및 C로 표시된 피크는 각각 삼량체, 이량체 및 단량체 분획물을 표시한다. 제2도는 B군연쇄상구균의 탄수화물 군에 결합하는 인체의 IgG단일 클론 항체인 단일 클론 항체 D3의 초기 단량체에 비교한 동종 접합체(이량체 또는 삼량체)의 EIA에 있어서 증가된 결합 활성을 나타낸 것이다. 제3도는 이. 콜리 K1의 캡슐 탄수화물에 결합하는 인체의 IgG단일 클론 항체인 단일 클론 항체 5E1-G의 초기 단량체에 비교한 동종접합체(이량체 또는 삼량체)의 증가된 결합 활성을 나타낸 것이다. 제4도는 인체의 유방 종양에 관련된 항원에 결합하는 쥐의 단일 클론 항체인 BR64의 초기 단량체의 비교한 동종접합체(이량체)의 EIA에서의 증가된 결합 활성을 나타낸 것이다.FIG. 1 shows the chromatogram of FPLCpropyl of an IgG homozygous mixture, where the x axis is the retention time and the y axis is A 280 , and the peaks labeled A, B and C represent the trimer, dimer and monomer fractions, respectively. FIG. 2 shows increased binding activity in the EIA of homologous conjugates (dimers or trimers) compared to the initial monomer of monoclonal antibody D3, a human IgG monoclonal antibody that binds to the carbohydrate group of group B streptococci. . Third is this. It shows the increased binding activity of homozygotes (dimers or trimers) compared to the initial monomer of monoclonal antibody 5E1-G, the human IgG monoclonal antibody that binds to the capsular carbohydrate of Colli K1. Figure 4 shows the increased binding activity in EIA of the comparative homozygotes (dimer) of the initial monomers of BR64, a mouse monoclonal antibody that binds to antigens associated with human breast tumors.
Claims (23)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57572590A | 1990-08-31 | 1990-08-31 | |
US575,725 | 1990-08-31 | ||
US74866291A | 1991-08-26 | 1991-08-26 | |
US748,662 | 1991-08-26 | ||
PCT/US1991/006195 WO1992004053A1 (en) | 1990-08-31 | 1991-08-29 | Homoconjugated immunoglobulins |
Publications (1)
Publication Number | Publication Date |
---|---|
KR930702029A true KR930702029A (en) | 1993-09-08 |
Family
ID=27076774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019930700605A KR930702029A (en) | 1990-08-31 | 1991-08-29 | Homozygous Immunoglobulins |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0547137A4 (en) |
JP (1) | JPH06500780A (en) |
KR (1) | KR930702029A (en) |
AU (1) | AU8506991A (en) |
CA (1) | CA2090317A1 (en) |
FI (1) | FI930846A (en) |
IE (1) | IE913071A1 (en) |
IL (1) | IL99363A0 (en) |
NZ (1) | NZ239617A (en) |
PT (1) | PT98840A (en) |
WO (1) | WO1992004053A1 (en) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2281300A (en) * | 1993-08-26 | 1995-03-01 | Merck & Co Inc | Anti-HIV antibody oligomer |
US6368596B1 (en) | 1997-07-08 | 2002-04-09 | Board Of Regents, The University Of Texas System | Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
KR101027427B1 (en) | 2004-11-12 | 2011-04-11 | 젠코어 인코포레이티드 | Fc VARIANTS WITH INCREASED BINDING TO FcRn |
EP1931709B1 (en) | 2005-10-03 | 2016-12-07 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
WO2007044616A2 (en) | 2005-10-06 | 2007-04-19 | Xencor, Inc. | Optimized anti-cd30 antibodies |
CA2658557C (en) | 2006-08-14 | 2015-12-01 | Xencor, Inc. | Optimized antibodies that target cd19 |
EP2064240A2 (en) | 2006-09-18 | 2009-06-03 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
ES2532461T3 (en) | 2007-12-26 | 2015-03-27 | Xencor, Inc. | FC variants with altered FCRN binding |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
WO2010112194A1 (en) | 2009-04-02 | 2010-10-07 | F. Hoffmann-La Roche Ag | Antigen-binding polypeptides and multispecific antibodies comprising them |
KR101431318B1 (en) | 2009-04-02 | 2014-08-20 | 로슈 글리카트 아게 | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
MX2011010158A (en) | 2009-04-07 | 2011-10-17 | Roche Glycart Ag | Bispecific anti-erbb-2/anti-c-met antibodies. |
PT2417156E (en) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Trivalent, bispecific antibodies |
MX2011010166A (en) | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Bispecific anti-erbb-3/anti-c-met antibodies. |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
CN104945509A (en) | 2009-09-16 | 2015-09-30 | 弗·哈夫曼-拉罗切有限公司 | Coiled coil and/or tether containing protein complexes and uses thereof |
WO2011091078A2 (en) | 2010-01-19 | 2011-07-28 | Xencor, Inc. | Antibody fc variants with enhanced complement activity |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
TWI426920B (en) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | Bispecific, bivalent anti-vegf/anti-ang-2 antibodies |
CA2807278A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann - La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
RU2644341C2 (en) | 2012-02-10 | 2018-02-08 | Дженентек, Инк. | Single-chain antibodies and other heteromultimers |
PE20142422A1 (en) | 2012-04-05 | 2015-01-21 | Hoffmann La Roche | BI-SPECIFIC ANTIBODIES AGAINST HUMAN TWEAK AND HUMAN IL 17 AND USES OF THE SAME |
ES2597228T3 (en) | 2012-06-27 | 2017-01-17 | F. Hoffmann-La Roche Ag | Procedure for the selection and production of objectification entities, such as targets, highly selective and multi-specific, customized, which contain at least two different binding entities, and use of these |
MX2014014804A (en) | 2012-06-27 | 2015-02-12 | Hoffmann La Roche | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof. |
WO2014006124A1 (en) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Covalently linked antigen-antibody conjugates |
CA2872192A1 (en) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Anti-biotin antibodies and methods of use |
CA2872184A1 (en) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Anti-theophylline antibodies and methods of use |
CN104341504B (en) | 2013-08-06 | 2017-10-24 | 百奥泰生物科技(广州)有限公司 | Bispecific antibody |
PL3083680T3 (en) | 2013-12-20 | 2020-06-29 | F. Hoffmann-La Roche Ag | Humanized anti-tau(ps422) antibodies and methods of use |
CA2933384A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
CN105873616B (en) | 2014-01-03 | 2020-06-05 | 豪夫迈·罗氏有限公司 | Covalently linked polypeptide toxin-antibody conjugates |
EP3089758B1 (en) | 2014-01-03 | 2021-01-27 | F.Hoffmann-La Roche Ag | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
AR100978A1 (en) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME |
WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
PL3313877T3 (en) | 2015-06-24 | 2020-11-02 | F. Hoffmann-La Roche Ag | Humanized anti-tau(ps422) antibodies and methods of use |
WO2017214151A1 (en) | 2016-06-06 | 2017-12-14 | Northwestern University | Fusion protein construct |
BR112020006339A2 (en) * | 2017-11-07 | 2020-11-03 | Hubit Genomix, Inc. | method for primary prevention of allergic disorders during childhood through specific immunosuppression of the ige class |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8422653D0 (en) * | 1984-09-07 | 1984-10-10 | Technology Licence Co Ltd | Monoclonal antibodies |
CA2045150A1 (en) * | 1989-11-07 | 1991-05-08 | Walt W. Shuford | Oligomeric immunoglobulins |
-
1991
- 1991-08-29 EP EP19910916502 patent/EP0547137A4/en not_active Ceased
- 1991-08-29 JP JP3515144A patent/JPH06500780A/en active Pending
- 1991-08-29 WO PCT/US1991/006195 patent/WO1992004053A1/en not_active Application Discontinuation
- 1991-08-29 CA CA002090317A patent/CA2090317A1/en not_active Abandoned
- 1991-08-29 KR KR1019930700605A patent/KR930702029A/en not_active Application Discontinuation
- 1991-08-29 AU AU85069/91A patent/AU8506991A/en not_active Abandoned
- 1991-08-30 PT PT98840A patent/PT98840A/en not_active Application Discontinuation
- 1991-08-30 NZ NZ239617A patent/NZ239617A/en unknown
- 1991-08-30 IE IE307191A patent/IE913071A1/en unknown
- 1991-09-01 IL IL99363A patent/IL99363A0/en unknown
-
1993
- 1993-02-25 FI FI930846A patent/FI930846A/en unknown
Also Published As
Publication number | Publication date |
---|---|
NZ239617A (en) | 1993-11-25 |
EP0547137A1 (en) | 1993-06-23 |
CA2090317A1 (en) | 1992-03-01 |
EP0547137A4 (en) | 1993-12-08 |
WO1992004053A1 (en) | 1992-03-19 |
IE913071A1 (en) | 1992-03-11 |
FI930846A0 (en) | 1993-02-25 |
AU8506991A (en) | 1992-03-30 |
JPH06500780A (en) | 1994-01-27 |
IL99363A0 (en) | 1992-08-18 |
PT98840A (en) | 1992-07-31 |
FI930846A (en) | 1993-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR930702029A (en) | Homozygous Immunoglobulins | |
Boulianne et al. | Production of functional chimaeric mouse/human antibody | |
US5055289A (en) | Interferon antibody therapeutic compositions having an extended serum half-life | |
US4844893A (en) | EX vivo effector cell activation for target cell killing | |
Shen et al. | Heteroantibody-mediated cytotoxicity: antibody to the high affinity Fc receptor for IgG mediates cytotoxicity by human monocytes that is enhanced by interferon-gamma and is not blocked by human IgG. | |
US6197298B1 (en) | Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals | |
JPH07246091A (en) | Method for selective production of hybridoma cell strain for producing monoclonal antibody having high cytotoxicity against human cd16-antigen and method for production of cd30-hrs-3-antibody for treating double specific monoclonal antibody and human tumor using said monoclonal antibody | |
KR927003816A (en) | Antibody to CD3 | |
DE69033181T2 (en) | IGA RECEPTOR-SPECIFIC MONOCLONAL ANTIBODIES | |
PT712307E (en) | METHODS FOR CONTROL OF THE POPULATION OF CELLS B | |
KR900013986A (en) | Monoclonal Antibodies to Tumor-Related Antigens (MAb_s), Methods for Making and Uses thereof | |
CA2000913A1 (en) | Family of high affinity antibodies for cancer treatment | |
Loop et al. | Two human tumor‐associated antigens, p155 and p210, detected by monoclonal antibodies | |
US5830473A (en) | Antibodies against T cells as therapeutics | |
Abbas et al. | Antigen‐antibody complexes suppress antibody production by mouse plasmacytoma cells in vitro | |
RU2127122C1 (en) | Composition showing cytotoxic effect, a method of treatment of leukemic cell in vitro | |
Masat et al. | A simpler sort of antibody. | |
Moroz et al. | Surface immunoglobulin of mouse thymus cells and its in vitro biosynthesis | |
Lundgren et al. | Cytotoxicity of human lymphocytes: antagonism between inducing processes | |
EP0569141A2 (en) | Methods of inhibiting the growth of multidrug resistant tumors with an antibody | |
JPS6127926A (en) | Cellular toxicity drug composition and selective killing method for target cell | |
CA2074662A1 (en) | Anti-idiotypic antibodies that mimic tnf | |
Starnes et al. | Heterogeneity of a murine B cell lymphoma. Isolation and characterization of idiotypic variants. | |
Mezzanzanica et al. | Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic | |
Stevenson et al. | Preparation and properties of FabIgG, a chimeric univalent antibody designed to attack tumour cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |